However, currently, there is no single compound that could combine PARP and CDK4/6 inhibition, which prompted us to develop new dual-targeting compound to improve the efficacy of PARP and CDK4/6 inhibits in breast and ovarian cancers. This evidence concerns the gene PARP1 and ovarian carcinoma.